PE59199A1 - Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa - Google Patents

Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa

Info

Publication number
PE59199A1
PE59199A1 PE1998000138A PE00013898A PE59199A1 PE 59199 A1 PE59199 A1 PE 59199A1 PE 1998000138 A PE1998000138 A PE 1998000138A PE 00013898 A PE00013898 A PE 00013898A PE 59199 A1 PE59199 A1 PE 59199A1
Authority
PE
Peru
Prior art keywords
alkylene
inhibitors
metaloprotease
tnf
inverted
Prior art date
Application number
PE1998000138A
Other languages
English (en)
Spanish (es)
Inventor
Marc Werner Andersen
Jennifer Badiang Stanford
Dulce Garrido Bubacz
Joseph Howing Chan
David John Cowan
Darryl Lynn Mcdougald
David Lee Musso
Michael Howard Rabinowitz
Robert William Wiethe
Robert Carl Andrews
Michael David Gaul
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE59199A1 publication Critical patent/PE59199A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE1998000138A 1997-02-26 1998-02-25 Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa PE59199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3911297P 1997-02-26 1997-02-26

Publications (1)

Publication Number Publication Date
PE59199A1 true PE59199A1 (es) 1999-06-24

Family

ID=21903750

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000138A PE59199A1 (es) 1997-02-26 1998-02-25 Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa

Country Status (16)

Country Link
EP (1) EP1019386A1 (is)
JP (1) JP2001513767A (is)
KR (1) KR20000075681A (is)
AP (1) AP9901631A0 (is)
AR (1) AR013070A1 (is)
AU (1) AU6822398A (is)
BR (1) BR9807763A (is)
CA (1) CA2281664A1 (is)
HR (1) HRP980096A2 (is)
IS (1) IS5159A (is)
NO (1) NO994103L (is)
PE (1) PE59199A1 (is)
PL (1) PL335378A1 (is)
TR (1) TR199902063T2 (is)
WO (1) WO1998038179A1 (is)
ZA (1) ZA981532B (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
GB2349884A (en) 1998-02-07 2000-11-15 British Biotech Pharm Antibacterial agents
AU5688999A (en) * 1998-08-26 2000-03-21 Glaxo Group Limited Formamide compounds as therapeutic agents
GB9818621D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therapeutic agents
AU5582899A (en) * 1998-08-26 2000-03-21 Glaxo Group Limited Formamides as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GB9918869D0 (en) * 1999-08-10 1999-10-13 British Biotech Pharm Antibacterial agents
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
EP1622617A2 (en) * 2003-02-11 2006-02-08 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
JP2009533318A (ja) * 2006-02-09 2009-09-17 ザ バーナム インスティテュート インスリン依存性糖尿病の処置のための膜1型マトリックスメタロプロテイナーゼのインヒビター
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ,インク. 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
DE69502378T2 (de) * 1994-01-20 1998-10-01 British Biotech Pharm Metalloproteinaseinhibitoren
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
ES2164264T3 (es) * 1995-11-23 2002-02-16 British Biotech Pharm Inhibidores de metaloproteinasas.

Also Published As

Publication number Publication date
CA2281664A1 (en) 1998-09-03
EP1019386A1 (en) 2000-07-19
NO994103L (no) 1999-10-25
JP2001513767A (ja) 2001-09-04
AR013070A1 (es) 2000-12-13
HRP980096A2 (en) 1998-12-31
AP9901631A0 (en) 1999-09-30
WO1998038179A1 (en) 1998-09-03
IS5159A (is) 1999-08-20
AU6822398A (en) 1998-09-18
ZA981532B (en) 1999-08-24
PL335378A1 (en) 2000-04-25
TR199902063T2 (xx) 1999-12-21
BR9807763A (pt) 2000-02-22
NO994103D0 (no) 1999-08-25
KR20000075681A (ko) 2000-12-26

Similar Documents

Publication Publication Date Title
PE59199A1 (es) Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa
TR200600172T1 (tr) Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.
HK20281A (en) Proline derivatives and related compounds
PE20081370A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
HRP20010273A9 (en) Two chamber cartridge for atomizers
EP0257102A4 (en) Agents for treating neurophathy
PE20090840A1 (es) Moleculas pequenas que contienen boro
PE20001419A1 (es) COMPLEJO DEL INHIBIDOR DE RAS-FARNESILTRANSFERASA Y SULFOBUTILETER-7-ß-CICLODEXTRINA O 2-HIDROXIPROPIL-ß-CICLODEXTRINA Y METODO
HUP0101172A1 (hu) Orto-antranilsavamid-származékok és antikoagulánsokként történő alkalmazásuk
HUP0300850A2 (hu) Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
AR050269A1 (es) Derivados amino de urea ciclicos, su preparacion y su uso farmaceutico como inhibidores de quinasa
GB904478A (en) Improved process of purifying plasminogen
BR0309357A (pt) Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas
BR0316561A (pt) Meios de filtração de sólidos de alta capacidade
PE20020339A1 (es) Derivados de pirrolidin como inhibidores de las metaloproteasas
DE602004016542D1 (de) Medikament auf basis von honig, seine herstellung und verwendung
WO2005010154A3 (en) 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity
DK1021404T3 (da) Azetidinonderivater til behandling af HCMV-infektioner
DE502006006013D1 (de) Substituierte thiazole und ihre verwendung zur herstellung von arzneimitteln
Sabri et al. Synthesis and spectral properties of some N‐(2‐benzimidazoyl)‐α‐aminoesters and their N‐oxides
KR900011764A (ko) 치환된 벤조[b]피란, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제
AT248631B (de) Verfahren zur Herstellung eines neuen Polypeptids
AR067059A1 (es) Compuestos heterociclicos insecticidas
RU2002111826A (ru) Ноотропное средство "Ноотобрил" в форме раствора для инъекций

Legal Events

Date Code Title Description
FA Abandonment or withdrawal